Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
275,000,000
-
Total 13F shares
-
13,927,007
-
Share change
-
-772,694
-
Total reported value
-
$27,020,000
-
Price per share
-
$1.93
-
Number of holders
-
48
-
Value change
-
-$1,811,564
-
Number of buys
-
12
-
Number of sells
-
29
Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) as of Q3 2022
As of 30 Sep 2022,
Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) was held by
48 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,927,007 shares.
The largest 10 holders included
FMR LLC, Nantahala Capital Management, LLC, VANGUARD GROUP INC, Artal Group S.A., BlackRock Inc., FRANKLIN RESOURCES INC, Sands Capital Ventures, LLC, Alphabet Inc., TYBOURNE CAPITAL MANAGEMENT (HK) LTD, and Laurion Capital Management LP.
This page lists
48
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.